| 000 | 01787 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513191955.0 | ||
| 264 | 0 | _c19991019 | |
| 008 | 199910s 0 0 eng d | ||
| 022 | _a0340-7004 | ||
| 024 | 7 |
_a10.1007/s002620050582 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKruit, W H | |
| 245 | 0 | 0 |
_aThe role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon alpha and lymphokine-activated killer cells. _h[electronic resource] |
| 260 |
_bCancer immunology, immunotherapy : CII _cSep 1999 |
||
| 300 |
_a331-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xcomplications |
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 |
_aCreatinine _xblood |
| 650 | 0 | 4 |
_aDiabetes Mellitus _xepidemiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xepidemiology |
| 650 | 0 | 4 |
_aImmunotherapy _xadverse effects |
| 650 | 0 | 4 |
_aInterferon-alpha _xadverse effects |
| 650 | 0 | 4 |
_aInterleukin-2 _xadverse effects |
| 650 | 0 | 4 |
_aKidney Diseases _xepidemiology |
| 650 | 0 | 4 | _aKidney Function Tests |
| 650 | 0 | 4 |
_aKidney Neoplasms _xcomplications |
| 650 | 0 | 4 |
_aKiller Cells, Lymphokine-Activated _xtransplantation |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNephrectomy |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSepsis _xepidemiology |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aSex Factors |
| 700 | 1 | _aSchmitz, P I | |
| 700 | 1 | _aStoter, G | |
| 773 | 0 |
_tCancer immunology, immunotherapy : CII _gvol. 48 _gno. 6 _gp. 331-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s002620050582 _zAvailable from publisher's website |
| 999 |
_c10431277 _d10431277 |
||